Glucotrack Submits IDE for Implantable Continuous Blood Glucose Monitoring Technology

Glucotrack, Inc. has submitted an Investigational Device Exemption (IDE) application to the U.S. FDA to begin a clinical study for its novel implantable continuous blood glucose monitoring technology, which aims to provide long-term, real-time blood glucose accuracy without requiring an on-body wearable. This submission demonstrates the company’s progress in preclinical development and aims to enhance the quality of life for people with diabetes.